{{Rsnum
|rsid=6784434
|Gene=FGF12
|Chromosome=3
|position=192362043
|Orientation=plus
|GMAF=0.4114
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=FGF12
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 2.7 | 31.0 | 66.4
| HCB | 38.0 | 52.6 | 9.5
| JPT | 37.2 | 49.6 | 13.3
| YRI | 36.1 | 46.3 | 17.7
| ASW | 38.6 | 33.3 | 28.1
| CHB | 38.0 | 52.6 | 9.5
| CHD | 36.7 | 42.2 | 21.1
| GIH | 31.7 | 50.5 | 17.8
| LWK | 26.4 | 60.9 | 12.7
| MEX | 13.8 | 43.1 | 43.1
| MKK | 26.9 | 51.9 | 21.2
| TSI | 1.0 | 29.3 | 69.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6784434
|Name_s=
|Gene_s=FGF12
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109380
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6784434
|overall_frequency_n=45
|overall_frequency_d=128
|overall_frequency=0.351562
|n_genomes=31
|n_genomes_annotated=0
|n_haplomes=42
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}